市場調查報告書

急性腎障礙(AKI)-市場洞察,流行病學及市場預測-2028

Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 736663
出版日期 內容資訊 英文 175 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
急性腎障礙(AKI)-市場洞察,流行病學及市場預測-2028 Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 175 Pages
簡介

急性腎障礙(AKI)的特徵,是由於腎小球過濾率迅速的降低,出現臨床性尿素和血肌酐急劇持續性的上升。這個疾病,導致腎功能的急劇降低,帶給電解質混亂和容量狀態變化。急性腎障礙,分類為腎前性,腎後性,內因性的不同階段。

本報告提供急性腎障礙(AKI)的相關調查,疾病概要,患者背景,主要7個國家診斷數量的預測,新藥概要,診斷指南,各治療藥物的市場規模,市場成長要素、障礙,競爭情形等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 調查概要

第3章 急性腎障礙(AKI)市場:概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第4章 疾病背景和概要

  • 簡介
  • 症狀
  • 急性腎障礙的類型
  • 分期區分
  • 危險因素
  • 病因
  • 病理生理學
  • 生物標記
  • 診斷

第5章 流行病學和患者人口

  • 主要的觀察
  • 主要7個國家的罹患數
  • 主要7個國家的出院時診斷數量

第6章 美國的急性腎障礙(AKI)市場

  • 前提和根據
  • 罹患數
  • 出院時診斷數量:各國
  • 出院時診斷數量:各病期
  • 風險要素
  • 腎臟移植後的內臟器官功能障礙(DGF)

第7章 歐洲的急性腎障礙(AKI)市場

  • 假設和根據
  • 德國
    • 罹患數
    • 出院時診斷數量:各國
    • 出院時診斷數量:各病期
    • 風險要素
    • 腎臟移植後的內臟器官功能障礙(DGF)
  • 法國
  • 義大利
  • 西班牙
  • 英國

第8章 日本的急性腎障礙(AKI)市場

  • 假設和根據
  • 罹患數
  • 出院時診斷數量:各國
  • 出院時診斷數量:各病期
  • 風險要素
  • 腎臟移植後的內臟器官功能障礙(DGF)

第9章 治療和預防

第10章 未滿足需求

第11章 新治療

  • Key Cross Competition

第12章 新藥

  • EA-230:Exponential Biotherapies
    • 臨床趨勢
    • 臨床實驗資訊
    • 安全性和有效性
    • 產品簡介
  • bRESCAP:Alloksys
  • recAP:AM Pharma
  • Reltecimod:AtoxBio
  • ASP1128:Astellas Pharma
  • Ruconest (Conestat alfa):Pharming Technologies
  • MB-102:MediBeacon
  • Levosimendan (Simdax):Orion Pharma

第13章 主要7個國家市場分析

  • 主要的觀察
  • 主要7個國家市場分析

第14章 美國市場預測:各國

  • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第15章 歐盟5國市場預測:各國

  • 德國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模

第16章 日本市場預測:各國

  • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第17章 急性腎障礙(AKI)的治療費趨勢

第18章 市場成長要素

第19章 市場障礙

第20章 DelveInsight的服務內容

第21章 附錄

  • 調查方法

第22章 免責聲明

第23章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0377

DelveInsight's 'Acute Kidney Injury (AKI)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AKI in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of AKI from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Acute Kidney Injury (AKI) - Disease Understanding and Treatment Algorithm

AKI is characterized by a rapid fall in glomerular filtration rate, clinically manifest as an abrupt and sustained rise in urea and creatinine. Life threatening consequences include volume overload, hyperkalaemia, and metabolic acidosis. As per the American Kidney Foundation organization, AKI was formerly called Acute Renal Failure. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes. Acute Kidney Injury is classified into three different phases including prerenal, postrenal and intrinsic renal. Pre-renal ARI is characterized by inadequate blood circulation to the kidneys, which leaves them to clean the body properly. Post-renal is characterized by acute obstruction to urinary flow which increases intratubular pressure and decreases GFR. Intrinsic AKI is the third type, which shows direct damage to kidneys by inflammation, toxins, drugs, and infections. The risk factors associated with AKI include age, exposure to nephrotoxins, family history, race and ethnicity, gender and others.

The DelveInsight Acute Kidney Injury market report gives the thorough understanding of the AKI by including details such as disease introduction, signs and symptoms, types of AKI, risk factors, causes, pathophysiology, stages of classification, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for AKI in the US, Europe, and Japan.

Acute Kidney Injury (AKI) Epidemiology

AKI, which is also known as Acute Renal Failure is characterized by azotemia that progresses over several hours or days, with or without oliguria. It is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Acute Kidney Injury in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

  • Incident Cases of Acute Renal Failure in the United States
  • Discharge Diagnosed Cases of Acute Renal Failure in the United States
  • Stage-Wise Discharged Diagnosed Cases of Acute Renal Failure in the United States
  • Risk Factor Associated Acute Renal Failure Cases in the United States
  • Renal Transplantation Associated Delayed Graft Function Cases in the United States

Risk factors associated with AKI has been observed from the study conducted by Orfeas Liangos et al. entitled, "Epidemiology and Outcomes of Acute Renal Failure in Hospitalized Patients: A National Survey". In the study, various risk factors are associated with ARF includes, Coronary artery disease, Congestive heart failure, Chronic kidney disease, Chronic lung disease, Cancer, Diabetes, Hypertension and HIV infection. The study also summarized that discharge diagnosis of ARF was also more commonly assigned to individuals with a coexisting diagnosis of congestive heart failure, chronic lung disease, chronic kidney disease, cancer, and HIV infection but less commonly to individuals with a coexisting diagnosis of coronary artery disease, diabetes, and hypertension.

Stage specific incident cases of acute kidney injury has been estimated on the basis of study conducted by Ostermann et al. entitled, "Challenges of defining acute kidney injury". This study compares the performance of the different ARF definitions. In this study, patients were segregated on the basis of stages in RIFLE and AKIN classification. The RIFLE criteria and the AKIN classification led to similar total incidences of ARF but different incidences and outcomes of the individual ARF stages. Although, the AKIN classification demonstrated a stepwise increase in risk of mortality.

Acute Kidney Injury (AKI) Drug Chapters

This segment of the Acute Kidney Injury report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment Acute Kidney Injury, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Acute Kidney Injury & awareness of the disease. The overall dynamics of Acute Kidney Injury market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Exponential Biotherapies, Alloksys, Atox Bio, Pharming Technologies, Angion Biomedica, Quark Pharmaceutical, Astellas Pharma, AM Pharma, Orion Pharma and MediBeacon will significantly increase the market during the forecast period (2019-2028).

Acute Kidney Injury (AKI) Market Outlook

AKI is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. Robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of Acute Kidney Injury market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of market which presently comprises of Biologics and molecules with new mechanisms of action. Currently, there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of Acute Kidney Injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs, which include various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Acute Kidney Injury in 7MM is expected to change from 2019-2028.

Acute Kidney Injury (AKI) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Acute Kidney Injury (AKI) such as ANG-3777 (BB3; Angion Biomedica), QPI1002 (Quark Pharmaceutical), ASP1128 (Astellas Pharma), MB-102 (MediBeacon), Ruconest (Conestat alfa; Pharming Technologies), recAP (AM Pharma), bRESCAP (Alloksys), Reltecimod (Atox Bio), EA-230 (Exponential Biotherapies), Simdax (Levosimendan; Orion Pharma) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Acute Kidney Injury (AKI) market.

Acute Kidney Injury (AKI) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Kidney Injury (AKI) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acute Kidney Injury (AKI) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Kidney Injury (AKI)market
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury (AKI)market
  • To understand the future market competition in the Acute Kidney Injury (AKI) market.

Table of Contents

1. Key Insights

2. The Report contains

3. Acute Kidney Injury Market (AKI): Overview at a Glance

  • 3.1. Market Share Distribution of AKI in 2017
  • 3.2. Market Share Distribution of AKI in 2028

4. Acute Kidney Injury (AKI): Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Symptoms
  • 4.3. Types of Acute Kidney Injury
  • 4.4. Stages Classification
  • 4.5. Risk Factors
  • 4.6. Etiology
  • 4.7. Pathophysiology
  • 4.8. Biomarkers
  • 4.9. Diagnosis

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. 7MM Total Incident Patient Population of AKI
  • 5.3. 7MM Total Discharge Diagnosed Population of AKI

6. United States

  • 6.1. Assumptions and Rationale
  • 6.2. Acute Kidney Injury Incident Cases in the US
  • 6.3. Acute Kidney Injury Discharge Diagnosed Cases in the US
  • 6.4. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in the US
  • 6.5. Acute Kidney Injury Risk Factor Associated Cases in the US
  • 6.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the US

7. EU5

  • 7.1. Assumptions and Rationale
  • 7.2. Germany
    • 7.2.1. Acute Kidney Injury Incident Cases in Germany
    • 7.2.2. Acute Kidney Injury Discharge Diagnosed Cases in Germany
    • 7.2.3. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in Germany
    • 7.2.4. Acute Kidney Injury Risk Factor Associated Cases in Germany
    • 7.2.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Germany
  • 7.3. France
    • 7.3.1. Acute Kidney Injury Incident Cases in France
    • 7.3.2. Acute Kidney Injury Discharge Diagnosed Cases in France
    • 7.3.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in France
    • 7.3.4. Acute Kidney Injury Risk Factor Associated Cases in France
    • 7.3.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in France
  • 7.4. Italy
    • 7.4.1. Acute Kidney Injury Incident Cases in Italy
    • 7.4.2. Acute Kidney Injury Discharge Diagnosed Cases in Italy
    • 7.4.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Italy
    • 7.4.4. Acute Kidney Injury Risk Factor Associated Cases in Italy
    • 7.4.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Italy
  • 7.5. Spain
    • 7.5.1. Acute Kidney Injury Incident Cases in Spain
    • 7.5.2. Acute Kidney Injury Discharge Diagnosed Cases in Spain
    • 7.5.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Spain
    • 7.5.4. Acute Kidney Injury Risk Factor Associated Cases in Spain
    • 7.5.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Spain
  • 7.6. United Kingdom
    • 7.6.1. Acute Kidney Injury Incident Cases in the UK
    • 7.6.2. Acute Kidney Injury Discharge Diagnosed Incident Cases in the UK
    • 7.6.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in the UK
    • 7.6.4. Acute Kidney Injury Risk Factor Associated Cases in the UK
    • 7.6.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the UK

8. Japan

    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Acute Kidney Injury Incident Cases in Japan
    • 8.1.3. Acute Kidney Injury Discharge Diagnosed Cases Japan
    • 8.1.4. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Japan
    • 8.1.5. Acute Kidney Injury Risk Factor Associated Cases in Japan
    • 8.1.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Japan

9. Treatment and Prevention

10. Unmet Needs

11. Emerging Therapies

  • 11.1. Key cross competition- Emerging Therapies

12. Emerging Therapies

  • 12.1. EA-230: Exponential Biotherapies
    • 12.1.1. Clinical Development
    • 12.1.2. Clinical Trials Information
    • 12.1.3. Safety and Efficacy
    • 12.1.4. Product Profile
  • 12.2. bRESCAP: Alloksys
    • 12.2.1. Other Developmental Activities
    • 12.2.2. Clinical Trials Information
    • 12.2.3. Safety and Efficacy
    • 12.2.4. Product Profile
  • 12.3. ANG-3777 (BB3) : Angion Biomedica
    • 12.3.1. Other Developmental Activities
    • 12.3.2. Clinical Trials Information
    • 12.3.3. Safety and Efficacy
    • 12.3.4. Product Profile
  • 12.4. QPI-1002: Quark Pharmaceuticals
    • 12.4.1. Other Developmental Activities
    • 12.4.2. Clinical Development
    • 12.4.3. Clinical Trial Information
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Advantages and Disadvantages
    • 12.4.6. Product Profile
  • 12.5. recAP: AM Pharma
    • 12.5.1. Other Developmental Activities
    • 12.5.2. Clinical Development
    • 12.5.3. Clinical Trial Information
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. Reltecimod: AtoxBio
    • 12.6.1. Other Developmental Activities
    • 12.6.2. Clinical Development
    • 12.6.3. Clinical Trial Information
    • 12.6.4. Safety and Efficacy
    • 12.6.5. Product Profile
  • 12.7. ASP1128: Astellas Pharma
    • 12.7.1. Other Developmental Activities
    • 12.7.2. Clinical Development
    • 12.7.3. Clinical Trial Information
    • 12.7.4. Safety and Efficacy
    • 12.7.5. Product Profile
  • 12.8. Ruconest (Conestat alfa): Pharming Technologies
    • 12.8.1. Other Developmental Activities
    • 12.8.2. Clinical Development
    • 12.8.3. Clinical Trial Information
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. MB-102: MediBeacon
    • 12.9.1. Other Developmental Activities
    • 12.9.2. Clinical Development
    • 12.9.3. Clinical Trial Information
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Product Profile
  • 12.10. Levosimendan (Simdax): Orion Pharma
    • 12.10.1. Clinical Development
    • 12.10.2. Clinical Trial Information
    • 12.10.3. Safety and Efficacy
    • 12.10.4. Product Profile

13. Acute Kidney Injury: 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of AKI in 7MM

14. United States Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of AKI
    • 14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook

  • 15.1. Germany Market Size
    • 15.1.1. Total Market size of AKI
    • 15.1.2. Market Size by Therapies
  • 15.2. France Market Size
    • 15.2.1. Total Market size of AKI
    • 15.2.2. Market Size by Therapies
  • 15.3. Italy Market Size
    • 15.3.1. Total Market size of AKI
    • 15.3.2. Market Size by Therapies
  • 15.4. Spain Market Size
    • 15.4.1. Total Market size of AKI
    • 15.4.2. Market Size by Therapies
  • 15.5. United Kingdom Market Size
    • 15.5.1. Total Market size of AKI
    • 15.5.2. Market Size by Therapies

16. Japan: Market Outlook

  • 16.1. Japan Market Size
    • 16.1.1. Total Market size of AKI
    • 16.1.2. Market Size by Therapies

17. Trends in the Cost of Therapies in Acute Kidney Injury

18. Market Drivers

19. Market Barriers

20. DelveInsight Capabilities

21. Appendix

  • 21.1. Report Methodology

22. Disclaimer

23. About DelveInsight

List of Tables

Table 1 Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification

Table 2 KDIGO Criteria

Table 3 Causes of AKI: Exposures and Susceptibilities for non-specific AKI

Table 4 Biomarkers of AKI

Table 5 RIFLE Criteria for AKI

Table 6 AKIN Criteria for AKI

Table 7 KDIGO Criteria for AKI

Table 8 Total Incident Population of AKI in the 7MM (2017-2028)

Table 9 Total Discharge Diagnosed Population of AKI in the 7MM (2017-2028)

Table 10 AKI Incident Cases in the US (2017-2028)

Table 11 AKI Discharge Diagnosed Cases in the US (2017-2028)

Table 12 AKI Stage-Wise Discharged Diagnosed Cases in the US (2017-2028)

Table 13 AKI Risk Factor Associated Cases in the US (2017-2028)

Table 14 AKI Renal Transplantation Associated Delayed Graft Function Cases in the US (2017-2028)

Table 15 AKI Incident Cases in Germany (2017-2028)

Table 16 AKI Discharge Diagnosed Cases in Germany (2017-2028)

Table 17 AKI Stage-Wise Incident Cases in Germany (2017-2028)

Table 18 AKI Risk Factor Associated Cases in Germany (2017-2028)

Table 19 AKI Renal Transplantation Associated Delayed Graft Function Cases in Germany (2017-2028)

Table 20 AKI Incident Cases in France (2017-2028)

Table 21 AKI Discharge Diagnosed Cases in France (2017-2028)

Table 22 AKI Stage-Wise Discharge Diagnosed Cases in France (2017-2028)

Table 23 AKI Risk Factor Associated Cases in France (2017-2028)

Table 24 AKI Renal Transplantation Associated Delayed Graft Function Cases in France (2017-2028)

Table 25 AKI Incident Cases in Italy (2017-2028)

Table 26 AKI Discharge Diagnosed Cases in Italy (2017-2028)

Table 27 AKI Stage-Wise Discharge Diagnosed Cases in Italy (2017-2028)

Table 28 AKI Risk Factor Associated Cases in Italy (2017-2028)

Table 29 AKI Renal Transplantation Associated Delayed Graft Function Cases in Italy (2017-2028)

Table 30 AKI Incident Cases in Spain (2017-2028)

Table 31 AKI Discharge Diagnosed Cases in Spain (2017-2028)

Table 32 AKI Stage-Wise Discharge Diagnosed Cases in Spain (2017-2028)

Table 33 AKI Risk Factor Associated Cases in Spain (2017-2028)

Table 34 AKI Renal Transplantation Associated Delayed Graft Function Cases in Spain (2017-2028)

Table 35 AKI Incident Cases in the UK (2017-2028)

Table 36 AKI Discharge Diagnosed Cases in the UK (2017-2028)

Table 37 AKI Stage-Wise Discharge Diagnosed Cases in the UK (2017-2028)

Table 38 AKI Risk Factor Associated Cases in the UK (2017-2028)

Table 39 AKI Renal Transplantation Associated Delayed Graft Function Cases in the UK (2017-2028)

Table 40 AKI Incident Cases in Japan (2017-2028)

Table 41 AKI Discharge Diagnosed Cases in Japan (2017-2028)

Table 42 AKI Stage-Wise Discharge Diagnosed Cases in Japan (2017-2028)

Table 43 AKI Risk Factor Associated Cases in Japan (2017-2028)

Table 44 AKI Renal Transplantation Associated Delayed Graft Function Cases in Japan (2017-2028)

Table 45 AKI Renal Replacement Therapy (RRT) Modalities for AKI

Table 46 Key Cross - Emerging Therapies

Table 47 EA-230, Clinical Trials Description, 2019

Table 48 bRESCAP, Clinical Trial Description, 2019

Table 49 ANG-3777 (BB3), Clinical Trial Description, 2019

Table 50 QPI-1002, Clinical Trial Description, 2019

Table 51 recAP, Clinical Trial Description, 2019

Table 52 Reltecimod, Clinical Trial Description, 2019

Table 53 ASP1128, Clinical Trials Description, 2019

Table 54 Ruconest (Conestat alfa), Clinical Trials Description, 2019

Table 55 MB-102, Clinical Trials Description, 2019

Table 56 Levosimendan (Simdax), Clinical Trials Description, 2019

Table 57 7 Major Market Size of AKI in USD Million (2017-2028)

Table 58 Market Size of AKI in the US, USD Million (2017-2028)

Table 59 Market size of AKI by therapies in the US, in USD Million (2017-2028)

Table 60 Market Size of AKI in Germany, USD Million (2017-2028)

Table 61 Market size of AKI by therapies in Germany, in USD Million (2017-2028)

Table 62 Market Size of AKI in France, USD Million (2017-2028)

Table 63 Market size of AKI by therapies in France, in USD Million (2017-2028)

Table 64 Market Size of AKI in Italy, USD Million (2017-2028)

Table 65 Market size of AKI by therapies in Italy, in USD Million (2017-2028)

Table 66 Market Size of AKI in Spain, USD Million (2017-2028)

Table 67 Market size of AKI by therapies in Spain, in USD Million (2017-2028)

Table 68 Market Size of AKI in the UK, USD Million (2017-2028)

Table 69 Market size of AKI by therapies in the UK, in USD Million (2017-2028)

Table 70 Market Size of AKI in Japan, USD Million (2017-2028)

Table 71 Market size of AKI by therapies in Japan, in USD Million (2017-2028)

Table 72 Trends in the Cost of Therapies in Acute Kidney Injury

List of Figures

Figure 1 Types of Acute Kidney Injury

Figure 2 Risk factors associated with Acute Kidney Injury

Figure 3 Common Causes of AKI

Figure 4 Pathophysiology of AKI

Figure 5 Biomarkers of AKI

Figure 6 Total Incident Patient Population of AKI in the 7MM (2017-2028)

Figure 7 Total Discharge Diagnosed Population of AKI in the 7MM (2017-2028)

Figure 8 AKI Incident Cases in the US (2017-2028)

Figure 9 AKI Discharge Diagnosed Cases in the US (2017-2028)

Figure 10 AKI Stage-Wise Discharged Diagnosed Cases in the US (2017-2028)

Figure 11 AKI Risk Factor Associated Cases in the US (2017-2028)

Figure 12 AKI Renal Transplantation Associated Delayed Graft Function Cases in the US (2017-2028)

Figure 13 AKI Incident Cases in Germany (2017-2028)

Figure 14 AKI Discharge Diagnosed Cases in Germany (2017-2028)

Figure 15 AKI Stage-Wise Incident Cases in Germany (2017-2028)

Figure 16 AKI Risk Factor Associated Cases in Germany (2017-2028)

Figure 17 AKI Renal Transplantation Associated Delayed Graft Function Cases in Germany (2017-2028)

Figure 18 AKI Incident Cases in France (2017-2028)

Figure 19 AKI Discharge Diagnosed Cases in France (2017-2028)

Figure 20 AKI Stage-Wise Discharge Diagnosed Cases in France (2017-2028)

Figure 21 AKI Risk Factor Associated Cases in France (2017-2028)

Figure 22 AKI Renal Transplantation Associated Delayed Graft Function Cases in France (2017-2028)

Figure 23 AKI Incident Cases in Italy (2017-2028)

Figure 24 AKI Discharge Diagnosed Cases in Italy (2017-2028)

Figure 25 AKI Stage-Wise Discharge Diagnosed Cases in Italy (2017-2028)

Figure 26 AKI Risk Factor Associated Cases in Italy (2017-2028)

Figure 27 AKI Renal Transplantation Associated Delayed Graft Function Cases in Italy (2017-2028)

Figure 28 AKI Incident Cases in Spain (2017-2028)

Figure 29 AKI Discharge Diagnosed Cases in Spain 2017-2028)

Figure 30 AKI Stage-Wise Discharge Diagnosed Cases in Spain (2017-2028)

Figure 31 AKI Risk Factor Associated Cases in Spain (2017-2028)

Figure 32 AKI Renal Transplantation Associated Delayed Graft Function Cases in Spain (2017-2028)

Figure 33 AKI Incident Cases in the UK (2017-2028)

Figure 34 AKI Discharge Diagnosed Cases in the UK (2017-2028)

Figure 35 AKI Stage-Wise Discharge Diagnosed Cases the UK (2017-2028)

Figure 36 AKI Risk Factor Associated Cases in the UK (2017-2028)

Figure 37 AKI Renal Transplantation Associated Delayed Graft Function Cases in the UK (2017-2028)

Figure 38 AKI Incident Cases of in Japan (2017-2028)

Figure 39 AKI Discharge Diagnosed Incident Cases in Japan (2017-2028)

Figure 40 AKI Stage-Wise Discharge Diagnosed Cases in Japan (2017-2028)

Figure 41 AKI Risk Factor Associated Cases in Japan (2017-2028)

Figure 42 AKI Renal Transplantation Associated Delayed Graft Function Cases in Japan (2017-2028)

Figure 43 Global Mortality of AKI

Figure 44 Stage-based management of Acute Kidney Injury (AKI)

Figure 45 Unmet Needs for AKI

Figure 46 7 Major Market Size of AKI in USD Million (2017-2028)

Figure 47 Market Size of AKI in the US, USD Million (2017-2028)

Figure 48 Market size of AKI by therapies in the US, in USD Million (2017-2028)

Figure 49 Market Size of AKI in Germany, USD Million (2017-2028)

Figure 50 Market size of AKI by therapies in Germany, in USD Million (2017-2028)

Figure 51 Market Size of AKI in France, USD Million (2017-2028)

Figure 52 Market size of AKI by therapies in France, in USD Million (2017-2028)

Figure 53 Market Size of AKI in Italy, USD Million (2017-2028)

Figure 54 Market size of AKI by therapies in Italy, in USD Million (2017-2028)

Figure 55 Market Size of AKI in Spain, USD Million (2017-2028)

Figure 56 Market size of AKI by therapies in Spain, in USD Million (2017-2028)

Figure 57 Market Size of AKI in the UK, USD Million (2017-2028)

Figure 58 Market size of AKI by therapies in the UK, in USD Million (2017-2028)

Figure 59 Market Size of AKI in Japan, USD Million (2017-2028)

Figure 60 Market size of AKI by therapies in Japan, in USD Million (2017-2028)

Figure 61 Market Drivers

Figure 62 Market Barriers

Back to Top